Email Updates

Search form

You are here

Informing the Research Enterprise: Dr. Carl Dieffenbach on future priorities for HIV research networks

top

AVAC
Friday, October 27, 2017
General

In this second webinar in a series with Dr. Carl Dieffenbach, the Director of the Division of AIDS (DAIDS) at the NIH’s National Institute of Allergy and Infectious Diseases, we discussed the future of investments in the NIH HIV clinical trial research networks in the US and internationally.

In this second webinar in a series with Dr. Carl Dieffenbach, the Director of the Division of AIDS (DAIDS) at the NIH’s National Institute of Allergy and Infectious Diseases, we discussed the future of investments in the NIH HIV clinical trial research networks in the US and internationally.

A recording of the first webinar is available here.

As background, every seven years, the NIH review the structure and funding of its HIV clinical research networks. This “network recompetition” process involves decisions that will help determine the focus and priorities of its HIV clinical trial networks through 2027, as well as the number and structures of the various networks that undertake this research. These are critical questions for advocates to weigh in on—whether you are in the US or not. Learn more with our factsheet.

The webinar included a brief introductory presentation from Dr. Carl Dieffenbach followed by a Q&A session. NIAID is also accepting public comments and questions online until November 30, 2017, so now is your chance!

Recording: YouTube / Audio / Slides